Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. junior Avg
|
New words:
accessible, adapt, adrenal, ancestry, annum, antagonist, apparent, Area, Assertio, benchmark, biopharmaceutical, Brexit, bulk, casualty, certiorari, cessation, CG, Circuit, classification, CODM, color, condemnation, constant, context, creed, de, deliberate, depletion, disability, disbursement, discriminate, disorder, divestiture, drawn, EBITDA, EEA, embrace, extinguished, extinguishment, Fargo, floating, fluidity, fundamentally, gender, genetic, guarantor, hybrid, hydrocortisone, hypogonadism, ID, immunology, infeasible, irrevocable, jatenzo®, Kyzatrex, led, Lender, lengthen, LIBOR, LPCN, marital, mental, middle, military, MN, molecularly, narrative, necessarily, NextPharma, ninety, nonrecurring, Notably, novo, objective, organizational, Otter, PCI, permanent, PK, pledge, PMA, portrayal, premium, prepay, prime, proud, provision, race, randomized, ratio, reader, receptor, redundancy, reintroduced, relaunch, repaid, rescinded, reside, residual, revolving, reward, rolling, sex, sexual, SPA, sublease, Supreme, swingline, talent, tied, top, tridecanoate, Unadjusted, undrawn, unused, Vai, veteran, viability, waived, writ, XR
Removed:
accidental, administering, alliance, Amerisource, appetite, approximated, AstraZeneca, awaiting, Basel, beneficially, Bergen, blood, born, BYDUREON, capable, circumstance, Codification, collaborate, collaborating, comparative, considerably, contact, convenient, cure, CVS, diet, dilute, disaggregated, DMARD, emptying, energy, escalation, Europe, exercisable, feasibility, feasible, Foundation, fulfilment, gastrointestinal, growing, headquartered, impacting, Impax, inflow, infringe, infringing, insolvent, insulin, intensifying, JCR, Ject, managerial, mature, Medi, methodology, MINE, move, Mylan, newer, noncash, nonqualified, Nypro, orally, overhead, Permatec, Pharmascience, Plymouth, practical, preventing, proceeding, pulmonary, remain, remitted, rest, reusable, run, secrete, sheathed, site, stimulating, stomach, stop, suburb, sugar, suit, SUPPLEMENTARY, titrated, traditional, Treasury, UK, unaudited, UNRESOLVED, week
Filing tables
Filing exhibits
Related press release
Associated ATRS transcripts
ATRS similar filings
Filing view
External links
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the registration statements (Nos. 333-167457, 333-180832, 333-189172, 333-196644, 333-211782, 333-232775 and 333-257345) on Form S-8, registration statements (Nos. 333-61950, 333-96739, 333-103958, 333-133218, 333-142323, 333-144748, and 333-217808) on Form S-3, and registration statements (Nos. 333-109114 and 333-114098) on Form S-2 of our report dated March 3, 2022, with respect to the consolidated financial statements of Antares Pharma, Inc. and the effectiveness of internal control over financial reporting.
/s/ KPMG LLP
Minneapolis, Minnesota
March 3, 2022